December 6, 2011

Sanofi Reports Positive Results for Once-daily Lyxumia® (lixisenatide) in Combination with Lantus® (insulin glargine) in Type 2 Diabetes

– Data from phase III GetGoal Duo 1 study show combination helped achieve HbA1c < 7.0% and significantly improved 2-h post-prandial glucose in uncontrolled patients –

 

Sanofi Reports Positive Results for Once-daily Lyxumia® (lixisenatide) in Combination with Lantus® (insulin glargine) in Type 2 Diabetes
– Data from phase III GetGoal Duo 1 study show combination helped achieve HbA1c < 7.0% and significantly improved 2-h post-prandial glucose in uncontrolled patients –

Paris, France – December 6, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia® (lixisenatide), its investigational GLP-1 agonist, in combination with Lantus® (insulin glargine) achieved its primary efficacy endpoint of significantly reducing HbA1c, with a significant improvement in post-prandial glucose, in the GetGoal Duo 1 study (also known as EFC10781*).